Facts:
Interpretation: The stock has declined dramatically (approximately 98% over the trailing year), consistent with challenges typical of early-stage biotechs facing dilution, cash burn, and clinical/regulatory hurdles. Performance reflects speculative trading rather than fundamental business progress.
Data Limitations/Assumptions: Financial figures are based on latest available TTM data from public sources (Yahoo Finance, StockAnalysis, etc.) as of mid-2026; exact quarterly breakdowns and future projections are limited due to the company's size and filing frequency. Historical price data shows extreme swings but exact intraday or real-time values are excluded per guidelines. No dividends paid.
| Period | Approximate Change | Notes |
|---|---|---|
| 1-Year | -98% | From peaks near $9+ to sub-$0.20 levels |
| YTD 2026 (through mid-July) | Significant decline (contextual ~70-80%+ drop from early highs) | Volatile with news-driven spikes |
| Recent Months (e.g., May-Jun 2026) | Sharp drops and rebounds (e.g., from ~$0.30+ to lower) | Linked to merger, warrant, and delisting news |
For full historical prices and charts: Yahoo Finance Historical Data | Nasdaq Historical Quotes
| Metric | LIMN Value | Industry Context (Biotech) |
|---|---|---|
| Revenue (TTM) | $0 / n/a | Typical for pre-revenue development-stage firms |
| Net Income (TTM) | ~-$11M | Common cash burn in R&D phase |
| EPS (TTM) | -$0.25 to -$0.58 | Negative due to development costs |
| Cash (mrq) | ~$1.91M | Limited runway; reliant on financings |
| Market Cap (recent) | $5M–$11M range | Microcap; high risk/volatility |
Sources and more details: Yahoo Finance Profile | StockAnalysis Overview | Simply Wall St
Facts: No specific analyst ratings, price targets, or coverage reports identified in major financial platforms (e.g., Yahoo Finance shows "1y Target Est --"; no Buy/Hold/Sell consensus listed).
Interpretation: Lack of analyst coverage is common for microcap biotechs with limited liquidity and early-stage pipelines; any investment decisions rely primarily on company disclosures rather than professional research.
Data Limitations: Absence of ratings does not imply positive or negative outlook; coverage may be nonexistent due to company size. Monitor SEC filings for updates.
Links for more: Yahoo Analyst Estimates | Nasdaq Analyst Info (if available)
Facts: As a development-stage company with no approved products or commercial sales, Liminatus Pharma has no traditional revenue-generating customers. Potential future "customers" could include pharmaceutical partners for licensing/out-licensing or patients in clinical trials.
Interpretation: The business model depends on successful clinical development leading to partnerships or acquisitions rather than direct sales.
Uncertainty: Pipeline is early (Phase 1 planned for IBA101); commercialization timeline uncertain and dependent on trial results, regulatory approval, and funding.
Facts: LIMN focuses on CD47-targeted immuno-oncology. Notable peers/competitors in the CD47 or broader immuno-oncology space include companies with similar or historical programs (many faced challenges like toxicity in earlier candidates).
| Company | Ticker | Focus/Asset | Stage/Notes |
|---|---|---|---|
| ALX Oncology | ALXO | Evorpacept (CD47-SIRPα blocker) | Clinical-stage; aims to reduce toxicity |
| Gilead Sciences (historical) | GILD | Magrolimab (acquired via Forty Seven) | Programs paused due to safety issues (anemia/thrombocytopenia) |
| Other immuno-oncology biotechs | Various (e.g., smaller peers) | CD47 or checkpoint inhibitors | Preclinical to clinical; high failure rate in class |
Interpretation: CD47 pathway has seen significant interest but limited clinical success to date due to on-target toxicities; LIMN positions IBA101 as a "next-generation" or "second-generation" candidate with potentially improved safety profile based on company disclosures (e.g., primate studies).
Data Limitations: Competitor list is illustrative based on public mentions of CD47 programs; broader oncology competitors exist but direct comparisons are challenging without detailed head-to-head data. Company claims of differentiation are interpretations from press releases and not independently verified here.
Links: Seeking Alpha on CD47 Context | Company pipeline details via SEC filings (search EDGAR for LIMN).
Facts: Liminatus Pharma, Inc. is a biopharmaceutical company focused on targeted cancer immunotherapies, primarily IBA101 (humanized anti-CD47 monoclonal antibody) for advanced solid cancers including non-small cell lung cancer. It has also pursued merger activity to expand into oncology cell therapies (e.g., with InnocsAI). Website: liminatuspharma.com (note: may have accessibility issues).
Uncertainty: Exact SPAC/merger history and prior crypto/digital asset explorations (mentioned in some 2025 releases) add complexity; verify via full SEC filings.
Links for full news: Yahoo Finance News | Nasdaq News | StockTitan
This analysis is for informational purposes only and not investment advice. All data derived from publicly available sources as of July 2026; markets and company status change rapidly. Always consult primary SEC filings (EDGAR), official company releases, and professional advisors. Microcap stocks like LIMN carry extreme risks including total loss of capital, dilution, and low liquidity.